Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

High-dose chemotherapy followed by blood stem cell transplantation is administered to
lymphoma patients with an intention to cure. However, high-dose chemotherapy simultaneously
causes damage to healthy tissues that frequently result in severe complications that lead to
hospitalization and can be life threatening. These severe complications involve the blood,
immune, gastro-intestinal systems, and other vital organs.

The purpose of this study is to determine if experimental therapy AB-205 (study drug) can
prevent or reduce the occurrence and duration of the severe chemotherapy related
complications when compared to placebo in patients with lymphoma undergoing treatment with
high-dose chemotherapy and blood stem cell transplantation. All patients, whether treated
with AB-205 or placebo, will receive standard preventive and supportive care therapies.
Phase III
Not Available
Not Available
Dholaria, Bhagirathbhai
Vanderbilt University


40 Years
Inclusion Criteria:

Age 40 years old

Diagnosis of Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL)

Candidates for HDT-AHCT with one of the following conditioning regimens:

BEAM (carmustine, etoposide, cytarabine, melphalan)

BeEAM (bendamustine, etoposide, cytarabine, melphalan)

Achieved CR or PR prior to planned HDT


Weight 1.6 ideal body weight (IBW) per Devine formula

Serum bilirubin 2 mg/dL, unless benign congenital hyperbilirubinemia

AST, ALT, and alkaline phosphatase
Creatinine clearance 30 ml/min (calculated by Cockcroft Gault)

LVEF 45% by MUGA or resting echocardiogram

Pulmonary function (FEV1 and corrected DLCO) 45% predicted

Willingness and ability to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions

Sexually active females of childbearing potential must have a negative urine pregnancy test and agree to use two accepted methods of contraception during the study and for 3 months after their last dose of study drug.

Male subjects who are sexually active and who are partners of females of childbearing potential: agreement to use two forms of contraception as in criterion 12 above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug

Ability to provide written informed consent.

Exclusion Criteria:

History of prior HCT

Primary CNS lymphoma

Lymphoma with CNS involvement at time of relapse prior to planned HDT-AHCT

Active malignancy other than the one for which the subject is undergoing HDT AHCT. Subjects with cervical carcinoma in situ or localized basal or squamous cell carcinoma treated with definitive surgery are eligible

Subjects with a serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring IV antibiotics

Subjects with a known history of HIV

Subjects who have known hypersensitivity reactions to bovine (cow) proteins or documented allergy to DMSO

Subject has other conditions that in the opinion of the investigator would require reduced dose (intensity) of BEAM or BeEAM regimens

To learn more about any of our clinical
trials, call 615-936-8422.